

malaria
NO MORE
united kingdom

ANNUAL REPORT AND ACCOUNTS



Year ended
31 December 2022

Company number
06648679

Charity number
1126222

CONTENTS

- 2 IMPACT IN BRIEF
- 4 CHAIR'S LETTER
- 6 CEO'S LETTER
- 5 WHY MALARIA
OUR MISSION
- 7 CHOGM AND THE KIGALI
SUMMIT ON MALARIA AND NTDs
- 9 SPOTLIGHT: DRAW THE LINE
AGAINST MALARIA
- 13 ZERO MALARIA CAMPAIGN
COALITION IN KENYA
- 15 LAUNCHING ZERO MALARIA BRITAIN
- 17 SPOTLIGHT: GLOBAL FUND
REPLENISHMENT
- 20 THANK YOU
- 21 DIRECTORS REPORT AND ACCOUNTS

Leaders and changemakers committed

\$4.25BN

to fight malaria and NTDs at the Kigali Summit in June 2022

A record-breaking total

\$15.7BN

pledged to the Global Fund to Fight AIDS, TB and Malaria in September 2022

1.07BN

digital and PR impressions generated by the Draw The Line Against Malaria campaign's second phase

34 countries increased their commitments

13 malaria-endemic countries stepped up their pledge

50+ new creative partners ready to support the malaria fight

24 malaria-endemic countries now signed up to the Zero Malaria Starts With Me movement

CHAIR'S LETTER



With the World Health Organization's World Malaria Report warning that the world was at risk of reversing the hard-won gains for the first time in nearly a decade, Malaria No More UK's priority in 2022 was to drive renewed commitment and energy into the global malaria fight.

We focussed on two major opportunities – the Commonwealth Heads of Government meeting in Kigali, Rwanda, and the 7th Replenishment of the Global Fund to Fight AIDS, Tuberculosis and Malaria.

We played a leading role in the impressive 2022 Kigali Summit on Malaria and Neglected Tropical Diseases. The build-up saw the reactivation of the multi-award-winning Zero Malaria Starts with Me – Draw the Line campaign, and at the Summit global leaders announced pledges totalling over \$4 billion.

We worked with our partners to push for more investment in the Global Fund's replenishment from around the world. In the UK, our campaign focussed on aid impact and the incredible contribution of British-backed science and building support and leadership around key UK political moments.

Despite the difficulties caused by the significant cuts to UK international development funding, our campaign helped achieve a £1 billion contribution, ensuring the UK remains as one of the leading donors in the fight against malaria.

This has also been a year of achievement for our exciting new programme in Kenya, delivered with national partners. World Malaria Day 2022 saw the launch of the first Zero Malaria Campaign Coalition as a locally led solution to the delivery of tailor-made in-country advocacy and communications.

The year's successes have been possible thanks to the unwavering commitment of Malaria No More UK's partners and all of those involved in the malaria fight. I am grateful to all of our partners for their contribution and collaboration, and I would like to thank both my predecessor Baroness Helene Hayman, and our former Chief Executive James Whiting, for their outstanding commitment and leadership. I extend a heartfelt welcome to Dr Astrid Bonfield as our new CEO, and look forward to working together to make our shared vision of ending malaria a reality.



Baroness Liz Sugg CBE
Board Chair

“Our central priority in 2022 has been driving renewed commitment and energy.”

CEO'S LETTER



Taking on the role of CEO at Malaria No More UK in January 2023, I have been struck by the evident passion and commitment to the global malaria fight, both from staff members in the UK and Kenya, and our many diverse partners and supporters.

This year we are laser-focused on bringing a sense of urgency back to the fight through an evolved campaign model and strengthening UK leadership and resourcing to malaria via Zero Malaria Britain. We will be advocating for funding for vitally important Product Development Partnerships, demonstrating British leadership in life sciences, convening a diverse group of experts across a wide range of malaria-related policy issues to advise Malaria No More UK on how the UK can best channel its malaria investments, and ensuring the UK follows through on its Global Fund commitment.

We will continue to bring our new Africa strategy to life via the Zero Malaria Campaign Coalition (ZMCC) in Kenya working with a multi-sectoral coalition of partners to deliver focused in-country advocacy and dynamic communications across three key endemic counties.

Looking forward to the organisation's wider drive to deliver accountability on the Commonwealth's commitment to work towards ending malaria by 2030, and the overarching goal of achieving the WHO's global technical strategy on the disease, we will continue our far-reaching engagement with influential global partners, as well as setting a new strategic horizon for our future.

This work is made possible thanks to multi-year funding partnerships from The Bill and Melinda Gates Foundation and Open Philanthropy Project as well as contributions from our donors and funders, a small selection of whom we can thank in this report. I would like to take this opportunity to also sincerely thank staff and partners for their tireless dedication to helping end this treatable and preventable disease and driving us all towards our common goal to end malaria within our lifetimes.



Dr Astrid Bonfield CBE
CEO, Malaria No More UK

“This year we are laser focused on bringing a sense of urgency back to the fight.”



WHY MALARIA?

Malaria is one of humankind's oldest and deadliest diseases. Fighting it has led to some of the greatest strides in global health in history. And yet, today, a child still dies from malaria **every minute** and half of the world's population remains at risk from this treatable and preventable disease.

With the world's attention focussed on COVID-19 in recent years, combined with rising biological and environmental threats and reduced funding, progress has not only plateaued but reversed, with 2021 recorded as one of malaria's worst years in recent history. However, scientific innovation and strong, resilient health programmes are saving and protecting lives. With popular and political will, strong leadership, and improved investment we can end malaria within our lifetimes.

OUR MISSION

Malaria No More UK's mission is to catalyse and inspire the global partnerships, leadership, and financing to end malaria in a generation. Our advocacy and communications expertise unlocks vital funds and drives the conversation and action needed to reach Zero Malaria.

In June 2022 Heads of State and Government, leaders from business, civil society and philanthropy, and health advocates from across Africa, came together in Rwanda for the Kigali Summit on Malaria and Neglected Tropical Diseases. Malaria No More UK helped lead a coalition of partners to deliver the Summit, which was hosted in Rwanda by His Excellency President Kagame alongside the Commonwealth Heads of Government Meeting.

Staged against a backdrop of an increasingly challenging funding landscape, the Summit featured bold pledges from leaders and changemakers targeted to accelerate the global fight to beat these deadly diseases, these totalled more than \$4 billion in commitments by the end of the day.

Powerful testimony from speakers including His Majesty King Charles III (at that time the Prince of Wales), His Excellency President Paul Kagame, WHO Director General Dr Tedros Adhanom Ghebreyesus, Melinda French Gates and acclaimed Nigerian novelist Chimamanda Ngozi Adichie, was joined with a rallying call from young people around the world demanding urgent action to end malaria within a generation. The culmination of the Zero Malaria Starts With Me Draw The Line Campaign saw the crowdsourced "Muundo" petition presented by young people to gathered leaders.

Responding to the Summit's clarion call, leaders at the Commonwealth Heads of Government Meeting expressed their renewed commitment to ending malaria by 2030 in the official CHOGM communique – an illustration of all-important leadership level determination not to turn their back on malaria at a critical moment.

CHOGM AND THE KIGALI SUMMIT ON MALARIA AND NTDS



Jesutomisin Apar
Medical laboratory scientist, Malaria Youth
Army champion and malaria survivor

“I met with a mother who could not afford the prescription given by the physician – she lost a two year old boy. That was heart-breaking for me... I see it as a call to action.

SPOTLIGHT: DRAW THE LINE AGAINST MALARIA

The Zero Malaria Starts With Me 'Draw The Line Against Malaria' campaign returned in 2022, injecting youth energy and malaria art into MTV's Africa Day concert.

Providing a vital drumbeat into the Kigali Summit in June, the launch of the second phase of Draw The Line brought together young people, talent, malaria champions and key partners together to put the spotlight on malaria in this critical year.

Working with Dentsu under a refreshed Zero Malaria brand, the global malaria community was able to harness talent and partners worldwide from David Beckham to Yemi Alade, Paramount to Meta, as well as deliver key messages into key global moments.

Having reached an audience of over 267 million (and with over a billion impressions), the campaign culminated with the delivery of the Muundo, a giant mural representing the voices of thousands of young people across Africa and the world who had come together to draw their line against malaria. The Muundo was delivered to leaders at the Kigali Summit.

The campaign also highlighted the stories and contributions of malaria champions like Jesutomisin Apar, a medical laboratory scientist and advocate. After surviving malaria in her teenage years, she resolved to be a part of ending it for good, both in her home country of Nigeria and across the world.



FROM SURVIVOR TO SUPERHERO

Jesutomisin remembers the painful headaches and fever when, as a teenager, she contracted malaria. Her parents took her to a clinic where she was diagnosed and treated – and luckily, she survived.

"I have a passion to end malaria and see it eradicated completely – from Nigeria to the outermost parts of Africa and the world at large," she says.

Jesutomisin became a medical laboratory scientist and works at the Olabisi Onabanjo University Teaching Hospital in Ogun State. She is involved in malaria diagnosis, as well as research and analysis that helps improve malaria control programmes.

As a champion for the African Leaders Malaria Alliance Youth Army, Jesutomisin raises awareness, advocating for accessible and affordable treatment.


Through public action, as well as innovative new tools to fight malaria from vaccines to rapid testing, Jesutomisin believes that a future free of malaria isn't just possible: it's inevitable. "To be able to have zero malaria in our life-time... it's actually achievable," she explains. "It's possible, and it starts from you and I."



Draw The Line
Against Malaria
Turn Up The Pressure

Yemi Alade
Nigerian Afropop singer and activist

“Imagine a world with Zero Malaria. The potential would be unmatched... The restrictions on life, on livelihood, that malaria has put on every one of us would be relinquished forever.”



Malaria is a significant public health problem in Kenya with the entire population at risk. 2022 saw us join Kenyan partners to launch the Zero Malaria Campaign Coalition (ZMCC), a multi-sectoral collaboration under the leadership of the Division of the National Malaria Programme, with Malaria No More UK and Kenyan NGO WACI Health working as the coalition secretariat collaborating with partners including Dentsu, Amref, PATH, and PMI.



The first of its kind, the ZMCC is designed to be a country-led solution mobilising the best of creative communications, media platforms, private sector and advocates to power a sustainable malaria campaign – shaping public perception of malaria and inspiring action from communities to national decision makers.

Already diverse and compelling spokespeople are lending their voices, from female scientists at the forefront of the malaria fight, to household names including athletes Eliud Kipchoge and Faith Kipyegon, as well as leading African band Sauti Sol. All have helped shine a spotlight on the race to Zero Malaria in 2022.

The combination of Malaria No More UK and WACI Health's advocacy and the communications power of the ZMCC are already helping drive action:

- Garnering **a commitment from the newly elected H.E. President** Dr William Samoei Ruto to increase investment and prioritise the end of this deadly disease
- Working with the Kenya Malaria Youth Army to support a **youth-led roadshow for World Malaria Day**. The roadshow visited three malaria endemic counties, securing coverage across TV, radio and print media and inspiring young people to join the malaria fight
- Partnering with the Kenyan Young Parliamentarians Association, leading to the **formation of the first Parliamentary Working Group on Malaria in Kenya**

ZERO MALARIA CAMPAIGN COALITION IN KENYA



Kenya makes pledge uplifted by

67%

to the Global Fund to Fight AIDS, TB and Malaria, as government commits to prioritise ending malaria

In December 2022,

15,000

fans attend Solfest, where hitmakers Sauti Sol officially join the Zero Malaria movement

Kenyan female scientists fighting malaria profiled on International Women's Day reach

1.9M

15

MPs form Kenya's first Parliamentary Working Group on Malaria

Katie Ewer
Professor of vaccine immunology
Jenner Institute, University of Oxford

“The reality is, we have all the tools we need to win the war against malaria. What we really need is political will and investment... to get this job done, because it is achievable.”

2022 was an important year for our UK advocacy effort as the government was asked to continue historic leadership on malaria with a renewed commitment to the Global Fund to Fight AIDS, Tuberculosis and Malaria. Against a backdrop of global financial turmoil and cuts to foreign aid budgets, we made the case for investing in malaria eradication at all levels of government, highlighting the importance to global health security, economic growth and critically, the health and wellbeing of communities in many of the world's poorest countries.

The launch of a new campaign 'Zero Malaria Britain' was designed to highlight to UK parliamentarians the power and leadership of British-backed science in saving and protecting lives from malaria; through ground-breaking malaria vaccines, resistance beating medicines and a new generation of insecticide-treated mosquito nets.

34 scientists, athletes, business leaders and malaria champions signed an open letter to the Prime Minister calling for a bold Global Fund pledge

Our campaigning was supplemented by support for the All-Party Parliamentary Group on Malaria and NTDs, now hosted by Malaria No More UK. Members took part in an active programme of roundtables, receptions, visits to scientific institutions and a Global Fund project in Rwanda, as they helped build cross-party support for ending malaria during an important year.

Ultimately our relentless campaigning – undertaken in close collaboration with partners working across the Global Fund's focus disease areas – played a vital role in lifting the ambition of the UK to deliver a £1 billion pledge to the Global Fund.

**LAUNCHING
ZERO MALARIA
BRITAIN**



SPOTLIGHT: GLOBAL FUND REPLENISHMENT

In September 2022, the United States hosted the Seventh Replenishment of the Global Fund to Fight AIDS, Tuberculosis and Malaria.

The Global Fund plays a vital role in making sure that life-saving innovations get to the right people in the right places at the right time. The replenishment aimed to raise a total of \$18 million to ensure that a further 20 million lives were saved by 2026. Given its importance to saving lives from malaria and in reinforcing global health systems, this was a primary focus for Malaria No More UK's advocacy and communications activity and partnerships in 2022. We worked in both the UK, and internationally, to put pressure on global leaders to step up their ambition.

After two years of postponement due to Covid-19 the Kigali Summit for Malaria and NTDs became a major platform upon which to strengthen the case for Global Fund investment by Commonwealth countries. It was supported by a powerful communications campaign highlighting youth voices and reaching over 19 million people. The Commonwealth Heads of Government communique included a statement prioritising the 7th Replenishment and in the wake of the Summit multiple Commonwealth countries including Australia, Canada, South Africa and Zero Malaria Campaign Coalition focus country Kenya, made their largest ever replenishment contributions.

As a co-founder and key donor to the Fund, the UK was amongst those countries asked to step up their previous commitments by 29% to meet setbacks in progress due to the effects of the Covid-19 pandemic. Malaria No More UK combined government advocacy with carefully targeted public communications during a politically unsettled time in the UK, and ultimately the UK Government announce a pledge of £1 billion – short of the requested increase but more than anticipated given the political climate.



WHY THE GLOBAL FUND MATTERS: NEW NETS IN TANZANIA

The distribution of new next-generation Interceptor® G2 mosquito nets, developed by BASF, was part of The New Nets Project, a four-year consortium led by British-based IVCC to obtain a coveted World Health Organisation (WHO) recommendation in March 2023. The project would not have been possible without vital funding grants from Unitaid and the Global Fund.

These new nets have been shown to reduce malaria incidence by almost half compared with standard nets and, by 2022, the initiative had distributed over 35 million nets across 13 countries, protecting an estimated 63 million people and averting millions of malaria cases.

Elizabeth George Kepha, one of the recipients of the new nets in Tanzania, shares the impact of this project for her and her children.

Elizabeth George Kepha, 33, is nine months pregnant and lives in Misungwi a town in the Mwanza region of Tanzania. She lives with her sister and her two children Helen Joseph, 8, and Elliot Joseph, 4. Raising her family alone, she received Interceptor® G2 mosquito nets in 2019, and found a life-changing way to avoid malaria and improve the welfare of her children.

“My husband and I are no longer together and so I support my children alone. Before the new nets arrived, we would sometimes have two episodes of malaria each month. This could cost between \$40 to \$70 per month depending on how serious the case was. We usually had to go to private clinics as the government hospitals often didn't have enough anti-malarial drugs available and you can get treated more quickly there.

“**We can rely on the new nets, and I feel much healthier. I am sure the new baby will be safe and protected.**

“For a single mother this is a lot of money that could have been spent on school fees or buying stock for my small shop. During my previous pregnancies I had to take drugs in case I got malaria and it affected the baby – now I am not taking anything because we can rely on the new nets, and I feel much healthier. I am sure this time that the new baby will be safe and protected from malaria.

“These new bed nets have made a big difference – the children have not had malaria for eight months now, and I'm no longer spending money on treating it. Instead, I can spend the money on school fees. I have also been able to buy a plot of land to build our own house and the future is looking much brighter.”





Women in Science
Fighting Malaria

Cynthia Waliaula
Medical doctor and policy analyst at Amref



“We’ve seen other infectious diseases be eliminated... We’re moving forward, there’s advances in technology. So I do feel that in my lifetime I will see a Zero Malaria world.”

Leadership Council

Andy Murray
David Beckham
Eliud Kipchoge

Our major funders during the year

The Bill and Melinda Gates Foundation
Fever-Tree Mixers
GSK
Medicines for Malaria Venture
Mr Patrice Motsepe
New Venture Fund
Open Philanthropy
The RBM Partnership to End Malaria

Partners donating resources, talents and time

Dentsu
Global Malaria Creative Collective
J&J Foundation
ZMCC Steering Committee

THANK YOU



DIRECTORS REPORT AND ACCOUNTS



KIGALI SUMMIT
ON MALARIA
AND NEGLECTED
TROPICAL DISEASES



Key information

Senior Management

- **Pervez Akhtar, Chief Operating Officer**
- **Dr Astrid Bonfield, Chief Executive (appointed December 2022)**
- **Vicky Gashe, Deputy Director of Communications**
- **Gareth Jenkins, Director of Advocacy**
- **Kate Wills, Director of Global Communications and Partnerships**
- **Amelia Yeo, Director of Philanthropy and Programme Partnerships**

During the year James Whiting, Chief Executive (October), Matthew Van Lierop, Chief Operating Officer (July), and Lilies Njanga, Africa Director (July), resigned.

Company number: 06648679

Charity number: 1126222

Registered Office

Room 202, 2nd Floor
Millbank Tower
21-24 Millbank
London
SW1P 4QP

Auditors

Sayer Vincent LLP
Invicta House, 108-114 Golden Lane
London
EC1Y 0TL

Bankers

CAF Bank (UK) Limited
25 Kings Hill Avenue
West Mailing Kent
ME19 4JQ

Triodos Bank
Deanery Road
Bristol
BS1 SAS

The Trustees are pleased to present their report together with the audited financial statements of the charity for the year to 31 December 2022. The accounts have been prepared in accordance with the accounting policies set out in note 1 to the accounts and comply with the Charity's Memorandum and Articles of Association, the Companies Act 2006 and the Statement of Recommended Practice 'Accounting and Reporting by Charities' (revised 2015).

Structure, governance and management governing document

Malaria No More United Kingdom is a charitable company limited by guarantee, incorporated on 16 July 2008 and registered as a charity on 8 October 2008. The company is governed by its Memorandum and Articles of Association.

Directors

The directors of the charitable company are its trustees for the purpose of charity law, and the members of the company limited by guarantee. Throughout this report they are collectively referred to as the Trustees.

The following individuals were Trustees at 31 December 2022 and served for the full year unless otherwise stated:

Baroness Liz Sugg (Chair - appointed February 2022)

Andrew Cook

Sarah Douglas (appointed February 2022)

Azra Ghani

Norman Mbazima

Sophie O'Connor (Treasurer)

Feyi Olubodun (appointed February 2022)

David Reddy

Eva Thorne

Linda Yueh

No Trustees had any beneficial interest in the charity and no remuneration of trustees is paid by the charity.

The Board of Trustees is responsible for the strategic direction, policy and overall governance of the charity.

The implementation of strategy once agreed and the day to day running and management of the charity's activities is delegated to the secretariat, led by the Chief Executive.

Recruitment and appointment of new trustees

The term of Baroness Hayman, as Chair of Trustees, Philip Thomas and Simon Bland all ended in February 2022. In February 2022 Baroness Liz Sugg was appointed as Chair of Trustees, and Sarah Douglas and Feyi Olubodun joined the board.

Linda Yueh resigned as a Trustee in January 2023. Andrew Cook's three year term as a Trustee ended in February 2023. Azra Ghani's three year term as a Trustee ended in March 2023. Sophie O'Connor resigned as a Trustee in June 2023.

Risk management

The Trustees regularly review the risks that the charity faces and are satisfied that relevant systems are in place to mitigate their exposure to major risks. The charity maintains a strategic risk register that is updated quarterly and reviewed at each Audit and Risk Committee meeting. The top three MNMUK Strategic Risks are:

1. UK government deprioritises malaria spending damaging MNMUK's reputation and its ability to raise new funding.
2. Global crises disproportionately reduce available media bandwidth diminishing MNMUK's campaign communications impact and its ability to raise new funding.
3. The ZMCC initiatives to support a national malaria strategy in Kenya fail, undermining the successful implementation of MNMUK's Africa strategy

Risks 1 and 2 directly impact the ability of MNMUK to raise future funding to achieve its strategic objectives. Risk 3 identifies the strategic challenges of MNMUK's activities in Africa. All risks have mitigation strategies and monitoring actions identified and are reviewed and updated regularly. The Audit and Risk Committee are mandated to review financial and risk related items and provide feedback and guidance to the Trustees. The Committee met four times in 2022.

MNMUK maintains an Operational Risk Register which is updated and reviewed regularly by the Leadership Team.

MNMUK has a Crisis Management Team, led by the Chief Executive Officer, which meets quarterly.

Public benefit

The Trustees confirm that they have complied with their duty under Section 17 (5) of the Charities Act 2011 to have due regard to the Charity Commission's general guidance on public benefit.

Senior executive remuneration

Salaries for permanent staff across all functions have been set in line with a range of market rate indicators and internal parity. Any salary adjustments made in the year were in line with the Salary Bandings Policy.

The charity publishes the salary of its key management personnel within its annual report. The number of staff paid over £60,000 is also published in accordance with the charity accounting requirements.

Structure, governance and management

Malaria No More UK is a registered charity and a company limited by guarantee without share capital and is governed by its memorandum and articles of association. The group includes a wholly owned subsidiary company, Malaria No More Trading, through which its 'cause marketing' activities are carried out.

The charity is governed by the Board of Trustees. The Board operates a quarterly meeting cycle with an Audit and Risk Committee meeting taking place before the main Board meeting. The Board, with the Executive Directors, review progress against organisation's strategic aims, the organisation's governance and structure, and consider the changing external environment. The retail operations were governed separately by the director of Malaria No More Trading, James Whiting. James Whiting stepped down in April 2023 to be replaced by Dr Astrid Bonfield.

In 2022, MNMUK registered the Kenya legal entity, which had been established in 2021, as a branch company of MNMUK.

Fundraising practices

As part of MNMUK's commitment to best practice, the charity adheres to the fundraising Codes of Practice set by the Fundraising Regulator and the Institute of Fundraising.

MNMUK is committed to ensuring that fundraising is open, respectful, and transparent to the public. The charity has several clearly documented policies and procedures, including a complaints policy, enabling any concerns from the public in relation to MNMUK's fundraising practices to be heard and addressed in a timely manner. During the year, no complaints have been received from the general public. There have also been no instances of non-compliance with the requirements of the fundraising code of practice.

The charity has a transparent way of working with vulnerable individuals. This fundraising policy clearly states all steps that should be followed to protect vulnerable people when offering support to the charity, ensuring that they have the relevant capacity to enable them to make the decision to donate.

Equity, Diversity and Inclusion

In late 2022 the MNM UK Equality Diversity and Inclusion Strategy and Roadmap was launched. The strategy provides a framework that will enable wide, comprehensive and progressive change: internally, through a focus on EDI in MNM UK's operations, behaviours and culture; and externally, in MNM UK's advocacy work, communication campaigns, and collaboration with partners and communities. MNM UK's premise is that staff, leaders, partners, stakeholders and communities have a responsibility and moral imperative to contribute to inclusivity goals. MNM UK wants to ensure that its working practices do not produce, reproduce or sustain the inequalities, exclusions and oppressions that we seek to address in the fight to end malaria.

Financial review

During 2022 MNMUK continued to receive support from longstanding partner the Bill and Melinda Gates Foundation. The period saw the close of a three-year grant (2019-2022) designed to "Galvanize progress to halve malaria across the Commonwealth and beyond". This was followed with the award of a new three-year grant (2022-2025) - "Unlocking the Path to Eradication"- with the first payment received in October 2022. This contribution is central to supporting MNMUK's work to help catalyse the political commitment, financing and collective action needed to reach international malaria reduction targets and help establish a pathway to achieving malaria elimination.

Grant funding of £437,874 was received in 2022 from the New Ventures Fund, RBM Partnership and several sector partners to support the delivery of the Kigali Malaria and NTD Summit and associated communications work.

As MNMUK continued to deliver Africa focused advocacy and communications, including the launch of the Zero Malaria Campaign Coalition in Kenya, and the continued development and delivery of Zero Malaria brand communications, restricted funding support was deployed and received from donors including the Motsepe Foundation and long-term supporters Fever-Tree and Rentokil Initial (continued deployment of funds donated in 2021).

Further designated funding was received from Medicines for Malaria Venture and pharmaceutical company GSK, to support MNMUK's UK and global advocacy and communications work.

As hosts of the secretariat for the All- Party Parliamentary Group (APPG) for Malaria and NTDs, MNMUK received £47,500 in restricted funding from APPG supporters.

MNMUK receives only limited income in the form of donations and fundraising from members of the public, meaning that the support of those individuals and community groups who do contribute to the charity is even more gratefully received. In 2022 almost £37,000 was received through public fundraising activities and a legacy gift, with more than £1,700 received through the HMRC Gift Aid scheme.

Expenditure during the period rose by £1,178,276 from £3,250,810 to £4,429,086. Of this total 76% was spent on direct charitable activities (2021: 79%). The expenditure on direct project costs rose from £916,083 in 2021 to £2,053,287 in 2022 supporting the Kigali Summit for Malaria and NTDs and the ZMCC initiative. The net decrease of resources for the year was £348,809 (2021: increase of £483,330). The decrease in resources was a result of the deployment of income recognised in 2021 for the Kigali Summit for Malaria and NTDs which was postponed from 2021 to 2022.

At the end of the period the charity's Balance Sheet remains strong with net assets of £2,006,889 compared to £2,355,698 in 2021. Restricted funds amounted to £860,785 compared to £881,030 in 2021. Total cash in hand available to the Charity has increased by £1,134,764 from £3,524,019 to £4,658,765 in 2022. This increase is principally the result of the early receipt of the first 12 month grant from Open Philanthropy for a major programme in 2023.

MNMUK benefited significantly from a wide range of pro-bono support provided to the charity. This is including, but not limited to, a range of gifts in kind received from celebrities, including David Beckham, global influencers including Yemi Alade, Johnson & Johnson through Living Goods, and highly valuable media support from the Dentsu Group. The value of these gifts in kind contributions in 2022 was some 80% higher than in 2021.

While the value of these contributions extends to many millions of pounds, only a portion of this is reflected in the accounts as Gifts In Kind (£675,108 in 2022; £367,941 in 2021) based on the MNM UK Gift In Kind Policy and the price that the charity would otherwise be prepared to pay in the open market.

Reserves

The Trustees' policy, updated in November 2022, is to maintain two reserves, together shown on the balance sheet as unrestricted funds; one, equivalent to the value of 4 months core operating costs (The Resilience Reserve), and two, reserves allocated to specific future projects to be delivered within 24 months (The Designated Reserves). The unrestricted reserves at the end of 2022 amounted to a total of £1,146,104 of which £946,104 was retained as the Resilience Reserve and £200,000 had been retained as the Designated Reserves.

Responsibilities of trustees in relation to the financial statements

The trustees (who are also the directors of Malaria No More UK for the purposes of company law) are responsible for preparing the Report of the Trustees and the financial statements in accordance with applicable law and United Kingdom Accounting Standards (United Kingdom Generally Accepted Accounting Practice).

Company law requires the trustees to prepare financial statements for each financial year which give a true and fair view of the state of affairs of the charitable company and of the incoming resources and application of resources, including the income and expenditure, of the charitable company for that period. In preparing those financial statements, the trustees are required to:

- Select suitable accounting policies and then apply them consistently;
- Observe the methods and principles in the Charity SORP;
- Make judgements and estimates that are reasonable and prudent;
- Prepare the financial statements on the going concern basis unless it is inappropriate to presume that the charitable company will continue in business.

The trustees are responsible for keeping proper accounting records which disclose with reasonable accuracy at any time the financial position of the charitable company and to enable them to ensure that the financial statements comply with the Companies Act 2006. They are also responsible for safeguarding the assets of the charitable company and hence for taking reasonable steps for the prevention and detection of fraud and other irregularities.

In so far as the trustees are aware:

- there is no relevant audit information of which the charitable company's auditors are unaware; and
- the trustees have taken all steps that they ought to have taken to make themselves aware of any relevant audit information and to establish that the auditors are aware of that information.

This report was approved by the Board of Trustees on 19 June 2023 and signed on its behalf by:

Baroness Elizabeth Sugg CBE, Board Chair

Independent auditors' report

Opinion

We have audited the financial statements of Malaria No More UK (the 'parent charitable company') and its subsidiaries (the 'group') for the year ended 31 December 2022 which comprise the consolidated statement of financial activities, the group and parent charitable company balance sheets, the consolidated statement of cash flows and the notes to the financial statements, including a summary of significant accounting policies. The financial reporting framework that has been applied in their preparation is applicable law and United Kingdom Accounting Standards, including FRS 102 *The Financial Reporting Standard applicable in the UK and Republic of Ireland (United Kingdom Generally Accepted Accounting Practice)*.

In our opinion, the financial statements:

- Give a true and fair view of the state of the group's and of the parent charitable company's affairs as of 31 December 2022 and of the group's incoming resources and application of resources, including its income and expenditure, for the year then ended
- Have been properly prepared in accordance with United Kingdom Generally Accepted Accounting Practice
- Have been prepared in accordance with the requirements of the Companies Act 2006 and the Charities Act 2011

Basis for opinion

We conducted our audit in accordance with International Standards on Auditing (UK) (ISAs (UK)) and applicable law. Our responsibilities under those standards are further described in the Auditor's responsibilities for the audit of the group financial statements section of our report. We are independent of the group and parent charitable company in accordance with the ethical requirements that are relevant to our audit of the financial statements in the UK, including the FRC's Ethical Standard, and we have fulfilled our other ethical responsibilities in accordance with these requirements. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion.

Conclusions related to going concern

In auditing the financial statements, we have concluded that the Trustees' use of the going concern basis of accounting in the preparation of the financial statements is appropriate.

Based on the work we have performed, we have not identified any material uncertainties relating to events or conditions that, individually or collectively, may cast significant doubt on Malaria No More UK's ability to continue as a going concern for a period of at least twelve months from when the financial statements are authorised for issue.

Our responsibilities and the responsibilities of the Trustees with respect to going concern are described in the relevant sections of this report.

Other information

The other information comprises the information included in the Trustees' annual report other than the group financial statements and the auditor's report thereon. The trustees are responsible for the other information contained within the annual report. Our opinion on the group financial statements does not cover the other information, and, except to the extent otherwise explicitly stated in our report, we do not express any form of assurance conclusion thereon. Our responsibility is to read the other information and, in doing so, consider whether the other information is materially inconsistent with the group financial statements, or our knowledge obtained in the course of the audit or otherwise appears to be materially misstated. If we identify such material inconsistencies or apparent material misstatements, we are required to determine whether this gives rise to a material misstatement in the group financial statements themselves. If, based on the work we have performed, we conclude that there is a material misstatement of this other information, we are required to report that fact. We have nothing to report in this regard.

Opinions on other matters prescribed by the Companies Act 2006

In our opinion, based on the work undertaken in the course of the audit:

- The information given in the Trustees' annual report for the financial year for which the financial statements are prepared is consistent with the financial statements
- The Trustees' annual report has been prepared in accordance with applicable legal requirements

Matters on which we are required to report by exception

In the light of the knowledge and understanding of the group and the parent charitable company and their environment obtained in the course of the audit, we have not identified material misstatements in the Trustees' annual report.

We have nothing to report in respect of the following matters in relation to which the Companies Act 2006 and Charities Act 2011 requires us to report to you if, in our opinion:

- Adequate accounting records have not been kept by the parent charitable company, or returns adequate for our audit have not been received from branches not visited by us; or
- The parent charitable company financial statements are not in agreement with the accounting records and returns; or
- Certain disclosures of Trustees' remuneration specified by law are not made; or
- We have not received all the information and explanations we require for our audit; or
- The directors were not entitled to prepare the financial statements in accordance with the small companies' regime and take advantage of the small companies' exemptions in preparing the Trustees' annual report and from the requirement to prepare a strategic report.

Responsibility of Trustees

As explained more fully in the statement of Trustees' responsibilities set out in the trustees' annual report, the Trustees (who are also the directors of the parent charitable company for the purposes of company law) are responsible for the preparation of the financial statements and for being satisfied that they give a true and fair view, and for such internal control as the trustees determine is necessary to enable the preparation of financial statements that are free from material misstatement, whether due to fraud or error. In preparing the financial statements, the trustees are responsible for assessing the groups' and the parent charitable company's ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless the trustees either intend to liquidate the group or the parent charitable company or to cease operations, or have no realistic alternative but to do so.

Auditors' responsibilities for the audit of financial statements

We have been appointed auditor under the Companies Act 2006 and section 151 of the Charities Act 2011 and report in accordance with those Acts.

Our objectives are to obtain reasonable assurance about whether the financial statements as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance but is not a guarantee that an audit conducted in accordance with ISAs (UK) will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these financial statements. Irregularities, including fraud, are instances of non-compliance with laws and regulations. We design procedures in line with our responsibilities, outlined above, to detect material misstatements in respect of irregularities, including fraud. The extent to which our procedures are capable of detecting irregularities, including fraud are set out below.

Capability of the audit in detecting irregularities

In identifying and assessing risks of material misstatement in respect of irregularities, including fraud and non-compliance with laws and regulations, our procedures included the following:

- We enquired of management, which included obtaining and reviewing supporting documentation, concerning the group's policies and procedures relating to:
 - Identifying, evaluating, and complying with laws and regulations and whether they were aware of any instances of non-compliance;
 - Detecting and responding to the risks of fraud and whether they have knowledge of any actual, suspected, or alleged fraud;
 - The internal controls established to mitigate risks related to fraud or non-compliance with laws and regulations.
- We inspected the minutes of meetings of those charged with governance.

- We obtained an understanding of the legal and regulatory framework that the group operates in, focusing on those laws and regulations that had a material effect on the financial statements or that had a fundamental effect on the operations of the group from our professional and sector experience.
- We communicated applicable laws and regulations throughout the audit team and remained alert to any indications of non-compliance throughout the audit.
- We reviewed any reports made to regulators.
- We reviewed the financial statement disclosures and tested these to supporting documentation to assess compliance with applicable laws and regulations.
- We performed analytical procedures to identify any unusual or unexpected relationships that may indicate risks of material misstatement due to fraud.
- In addressing the risk of fraud through management override of controls, we tested the appropriateness of journal entries and other adjustments, assessed whether the judgements made in making accounting estimates are indicative of a potential bias and tested significant transactions that are unusual or those outside the normal course of business.

Because of the inherent limitations of an audit, there is a risk that we will not detect all irregularities, including those leading to a material misstatement in the financial statements or non-compliance with regulation. This risk increases the more that compliance with a law or regulation is removed from the events and transactions reflected in the financial statements, as we will be less likely to become aware of instances of non-compliance. The risk is also greater regarding irregularities occurring due to fraud rather than error, as fraud involves intentional concealment, forgery, collusion, omission or misrepresentation.

A further description of our responsibilities is available on the Financial Reporting Council's website at: www.frc.org.uk/auditorsresponsibilities. This description forms part of our auditor's report.

Use of our report

This report is made solely to the charitable company's members as a body, in accordance with Chapter 3 of Part 16 of the Companies Act 2006 and section 144 of the Charities Act 2011 and regulations made under section 154 of that Act. Our audit work has been undertaken so that we might state to the charitable company's members those matters we are required to state to them in an auditor's report and for no other purpose. To the fullest extent permitted by law, we do not accept or assume responsibility to anyone other than the charitable company and the charitable company's members as a body, for our audit work, for this report, or for the opinions we have formed.

Jonathan Orchard (Senior statutory auditor) 19 June 2023

for and on behalf of Sayer Vincent LLP, Statutory Auditor Invicta House, 108-114 Golden Lane, LONDON, EC1Y 0TL

Balance sheets

As at 31 December 2022		Company no. 06648679			
		The group		The charity	
		2022	2021	2022	2021
Note		£	£	£	£
Fixed assets:					
Tangible assets	9	12,805	9,249	12,805	9,249
Investments	10	502,571	-	502,571	1
		515,376	9,249	515,376	9,250
Current assets:					
Debtors	12	273,113	466,318	253,323	87,728
Cash at bank and in hand		4,722,664	3,614,161	4,658,765	3,524,019
		4,995,777	4,080,479	4,912,087	3,611,747
Liabilities:					
Creditors: Deferred income	13	(3,263,915)	(1,511,608)	(3,263,915)	(1,511,608)
Creditors: amounts falling due within one year	13	(240,350)	(222,421)	(229,720)	(154,908)
		(3,504,264)	(1,734,029)	(3,493,634)	(1,666,516)
Net current assets		1,491,513	2,346,450	1,418,453	1,945,231
Total assets less current liabilities		2,006,889	2,355,698	1,933,829	1,954,481
Funds:					
Unrestricted income funds	18a	1,146,104	1,474,668	1,073,045	1,046,325
Restricted income funds		860,785	881,030	860,785	908,156
Resilience reserve		946,104	1,474,668	946,104	1,474,668
Designated reserve		200,000	-	200,000	-
Total unrestricted funds		1,146,104	1,474,668	1,073,045	1,046,325
Total funds		2,006,889	2,355,698	1,933,830	1,954,481

Consolidated statement of cash flows

For the year ended 31 December 2022					
	Note	2022		2021	
		£	£	£	£
Cash flows from operating activities					
Net income for the reporting period (as per the statement of financial activities)		(348,809)		483,330	
Depreciation charges		10,676		7,662	
Increase in debtors		193,205		(141,712)	
Increase in creditors		17,929		28,849	
Increase/(decrease) in deferred income		1,752,306		(277,730)	
Net cash provided by operating activities		1,625,307		100,399	
Cash flows from investing activities:					
Purchase of fixed assets		(14,232)		(10,553)	
Net cash used in investing activities		(14,232)		(10,553)	
Change in cash and cash equivalents in the year		1,611,075		89,846	
Cash and cash equivalents at the beginning of the year		3,614,161		3,524,315	
Cash and cash equivalents at the end of the year		5,225,236		3,614,161	

Approved by the Board of Trustees on 19 June 2023 and signed on its behalf by:

Baroness Elizabeth Sugg CBE, Board Chair

For the year ended 31 December 2022

1 Accounting policies

a) Statutory information

Malaria No More UK is a charitable company limited by guarantee. It is registered in England and Wales and incorporated in the United Kingdom.
The registered office address is Room 202, 2nd Floor, Millbank Tower, 21-24 Millbank, London, SW1P 4QP.

b) Basis of preparation

The financial statements have been prepared in accordance with Accounting and Reporting by Charities: Statement of Recommended Practice applicable to charities preparing their accounts in accordance with the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102) - (Charities SORP FRS 102), The Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102) and the Companies Act 2006.

Assets and liabilities are initially recognised at historical cost or transaction value unless otherwise stated in the relevant accounting policy or note.

In applying the financial reporting framework, the trustees have made a number of subjective judgements, for example in respect of significant accounting estimates. Estimates and judgements are continually evaluated and are based on historical experience and other factors, including expectations of future events that are believed to be reasonable under the circumstances. The nature of the estimation means the actual outcomes could differ from those estimates. Any significant estimates and judgements affecting these financial statements are detailed within the relevant accounting policy below.

c) Public benefit entity

The charity meets the definition of a public benefit entity under FRS 102.

d) Going concern

The trustees consider that there are no material uncertainties about the charity's ability to continue as a going concern.

The trustees do not consider that there are any sources of estimation uncertainty at the reporting date that have a significant risk of causing a material adjustment to the carrying amounts of assets and liabilities within the next reporting period.

e) Income

All incoming resources are included in the statement of financial activities when the charity is entitled to the income and the amount can be quantified with reasonable accuracy. The following specific policies are applied to particular categories of income.

- (i) Donations and legacies are received by way of grants, donations and gifts and are included in full in the statement of financial activities when receivable. Grants receivable are recognised when the charity becomes unconditionally entitled to the grant. A gift aid donation from the trading subsidiary to the charity is accrued when the gift aid payment is payable under a legal obligation. Measurement is at the fair value receivable, which is the transaction value.

For the year ended 31 December 2022

h) Operating leases

Rental costs are charged on a straight line basis over the term of the lease.

i) Tangible fixed assets

Tangible fixed assets costing over £500 (including any incidental expenses of acquisition) are capitalized. Depreciation is provided at rates calculated to write off the cost on a straight line basis over their expected useful economic life. The rate of depreciation is 33.33% per annum for all assets.

j) Foreign currency

Transactions in foreign currencies are initially recorded in the entity's functional currency, which is pound sterling, by applying the spot exchange rate on the date of the transaction. Monetary assets and liabilities denominated in foreign currencies are translated at the rate of exchange on the balance sheet date. All differences are taken to the statement of financial activities.

k) Debtors

Trade and other debtors are recognised at the settlement amount due after any trade discount offered. Prepayments are valued at the amount prepaid net of any trade discounts due.

l) Cash at bank and in hand

Cash at bank and cash in hand includes cash and short term highly liquid investments with a short maturity of three months or less from the date of acquisition or opening of the deposit or similar account.

m) Creditors and provisions

Creditors and provisions are recognised where the charity has a present obligation resulting from a past event that will probably result in the transfer of funds to a third party and the amount due to settle the obligation can be measured or estimated reliably. Creditors and provisions are normally recognised at their settlement amount after allowing for any trade discounts due.

n) Deferred income

Income is deferred by the charity only if there is a donor-imposed condition or restraint preventing the recognition of restricted income in the SoFA. This is in line with the charity's income recognition policy.

o) Financial instruments

The charity only has financial assets and financial liabilities of a kind that qualify as basic financial instruments. Basic financial instruments are initially recognised at transaction value and subsequently measured at their settlement value.

2 Income from donations and legacies

	2022			2021		
	Unrestricted £	Restricted £	Total £	Unrestricted £	Restricted £	Total £
Donations	40,027	454,894	494,921	204,454	175,000	379,454
Donated services	675,108	-	675,108	367,941	-	367,941
	715,135	454,894	1,170,029	572,395	175,000	747,395

Donated services represent pro bono time of numerous celebrities, legal and catering services and communications and PR support from a number of agencies.

3 Income from charitable activities

	2022			2021		
	Unrestricted £	Restricted £	Total £	Unrestricted £	Restricted £	Total £
Grants		2,795,957	2,795,957		2,539,160	2,539,160

4 Income from other trading activities

	2022			2021		
	Unrestricted £	Restricted £	Total £	Unrestricted £	Restricted £	Total £
Cause related marketing	100,071		100,071	442,420		442,420

For the year ended 31 December 2022

5a Analysis of expenditure (current year)

	Raising funds £	Charitable activities		Governance £	Support costs £	2022 Total £	2021 Total £
		UK Campaign and Activities £	African Campaign and Activities £				
Staff costs (Note 7)	169,636	792,449	528,300	16,822	319,626	1,826,834	1,869,289
Direct project costs	-	847,275	1,206,012	-	-	2,053,287	916,083
HR, recruitment and training	-	-	-	13,636	122,723	136,359	118,097
Legal and professional	-	-	-	-	10,378	10,378	7,551
Premises	-	-	-	-	95,050	95,050	145,470
Office running costs	-	-	-	-	108,686	108,686	108,463
Audit	-	-	-	12,900	-	12,900	11,220
Other costs	-	-	-	4,234	107,533	111,767	48,812
Fundraising costs	73,826	-	-	-	-	73,826	25,826
	243,462	1,639,724	1,734,311	47,592	763,996	4,429,086	3,250,811
Support costs	76,400	371,289	316,307		(763,996)		
Governance costs	4,759	23,129	19,704	(47,592)			
Total expenditure 2022	324,621	2,034,143	2,070,323	-	-	4,429,086	
Total expenditure 2021	316,871	1,615,136	1,318,804	-	-		3,250,811

Included in direct project costs are grants payable of £158,299 (2021: nil) to one partner, WACI Health.

5b Analysis of expenditure (prior year)

	Raising funds £	Charitable activities		Governance £	Support costs £	2021 Total £
		UK Campaign and Activities £	African Campaign and Activities £			
Staff costs (Note 7)	210,637	776,510	517,673	18,087	346,382	1,869,289
Direct project costs	-	407,786	508,297	-	-	916,083
HR, recruitment and training	-	-	-	11,810	106,288	118,097
Legal and professional	-	-	-	-	7,551	7,551
Premises	-	-	-	-	145,470	145,470
Office running costs	-	-	-	-	108,463	108,463
Audit	-	-	-	11,220	-	11,220
Other costs	-	-	-	1,100	47,712	48,812
Fundraising costs	25,826	-	-	-	-	25,826
	236,463	1,184,296	1,025,970	42,217	761,865	3,250,811
Support costs	76,187	408,220	277,459	-	(761,865)	
Governance costs	4,222	22,620	15,375	(42,217)		
Total expenditure 2021	316,871	1,615,136	1,318,804	-	-	3,250,811

For the year ended 31 December 20226 **Net income for the year**

This is stated after charging / (crediting):

	2022 £	2021 £
Depreciation	10,675	7,660
Operating lease rentals:		
Property	79,489	131,352
Auditor's remuneration (excluding VAT):		
Audit	10,750	9,350

7 **Analysis of staff costs, trustee remuneration and expenses, and the cost of key management personnel**

Staff costs were as follows:

	2022 £	2021 £
Salaries and wages	1,499,880	1,547,742
Pension	152,070	150,764
Social security costs	174,884	170,783
	1,826,834	1,869,289

	2022 No.	2021 No.
The average number of full-time equivalent employees during the period was	25	30
The average number of staff (headcount basis) during the period was	29	33

The number of staff whose emoluments were in excess of £60,000 during the year were as follows:

	2022 No.	2021 No.
£60,001 - £70,000	5	4
£70,001 - £80,000	1	2
£80,001 - £90,000	2	2
£90,001 - £100,000	1	-
£100,001 - £110,000	-	1

The total employee benefits (including pension contributions and employer's national insurance) of the key management personnel were £535,390.44 (2021: £616,115.71).

The charity did not pay to its trustees any remuneration during the year (2021: £nil) or any reimbursed trustee expenses (2022: £343.03).

8 **Taxation**

The charity is exempt from tax on income and gains falling within section 505 of the Taxes Act 1988 or section 252 of the Taxation of Chargeable Gains Act 1992 to the extent that these are applied to its charitable objects.

For the year ended 31 December 2022**9 Tangible fixed assets - charity and group**

	Computer equipment £	Total £
Cost		
At the start of the year	43,841	43,841
Additions in year	14,232	14,232
Disposals in year	-	-
At the end of the year	58,073	58,073
Depreciation		
At the start of the year	34,592	34,592
Charge for the year	10,676	10,676
Eliminated on disposal	-	-
At the end of the year	45,268	45,268
Net book value At the end of the year	12,805	12,805
At the start of the year	9,248	9,248

All of the above assets are used for charitable purposes.

10 Subsidiary undertaking

The Consolidated Statement of Financial Activities includes the results of the charity and its wholly owned subsidiary Malaria No More UK Trading Limited, which conducts trading and merchandising activities on behalf of the charity. The company pays all of its profits to the charity by a gift aid donation. Malaria No More UK Trading Limited is registered under company number 07621448 and it's registered office is at The Foundry, 17 Oval Way, London, SE11 5RR. A summary of the results of the subsidiary is shown below:

	2022 £	2021 £
Turnover	100,071	442,420
Cost of sales & administrative expenses	(27,012)	(27,104)
Gross profit	73,059	415,315
Retained earnings		
Total retained earnings brought forward	401,219	(14,098)
Profit/loss for the financial year	73,059	415,315
Distribution under Gift Aid to parent charity	(401,219)	-
Total retained earnings carried forward	73,059	401,218
The aggregate of the assets, liabilities and reserves was:		
Assets	93,899	468,732
Liabilities	(20,841)	(67,513)
Reserves	73,059	401,219

11 Parent charity

The parent charity's gross income and the results for the year are disclosed as follows:

	2022 £	2021 £
Gross income	4,006,586	3,317,833
Result for the year	(421,867)	67,903

For the year ended 31 December 2022**12 Debtors**

	The group		The charity	
	2022 £	2021 £	2022 £	2021 £
Trade debtors	120,999	448,526	90,999	69,936
Inter group debtor		-	10,210	-
Rent deposit	5,183	5,183	5,183	5,183
Accrued income	124,365		124,365	
Other debtors	22,566	12,609	22,566	12,609
	273,113	466,318	253,323	87,728

13 Creditors: amounts falling due within one year

	The group		The charity	
	2022 £	2021 £	2022 £	2021 £
Trade creditors	57,925	67,615	57,295	67,615
Inter group creditor				8,797
Deferred income	3,263,915	1,511,608	3,263,915	1,511,608
Sundry creditors and accruals	182,425	154,806	172,425	78,496
	3,504,264	1,734,029	3,493,634	1,666,517

14 Deferred income

Deferred income comprises BMGF and OP income received during the 2022 financial year which was not available for spending in the year. The deferred balance is expected to be utilised over the 2023 financial year in line with the grant agreement.

	The group		The charity	
	2022 £	2021 £	2022 £	2021 £
Balance at the beginning of the year	1,511,608	1,789,338	1,511,608	1,789,338
Amount released to income in the year	(2,650,765)	(2,858,955)	(2,650,765)	(2,858,955)
Amount deferred in the year	4,576,826	2,581,225	4,576,826	2,581,225
Balance at the end of the year	3,437,670	1,511,608	3,437,670	1,511,608

15 Pension scheme

The charity operates an auto-enrolment pension scheme with The Peoples Pension. All staff are eligible, and the charity pays 10% employer's contribution in addition to any personal contribution made by the staff themselves. The charity also allows staff who have "opted out" of the auto-enrolment scheme to nominate a personal pension plan to receive their pension contribution.

Pension costs stated in note 9 and charged in the Statement of Financial Activities represent the total contributions payable by the charity in the year.

16a Analysis of group net assets between funds (current year)

	General unrestricted £	Restricted funds £	Total funds £
Tangible fixed assets	12,805	-	12,805
Investments	502,570	-	502,570
Current assets	871,077	4,124,700	4,995,777
Current liabilities	(240,350)	(3,263,915)	(3,504,264)
Net assets at 31 December 2022	1,146,103	860,785	2,006,888

For the year ended 31 December 2022**16b Analysis of group net assets between funds (prior year)**

	General unrestricted £	Restricted funds £	Total funds £
Tangible fixed assets	9,249	-	9,249
Current assets	1,687,840	2,392,639	4,080,479
Current liabilities	(222,421)	(1,511,608)	(1,734,029)
Net assets at 31 December 2021	1,474,668	881,031	2,355,699

17 Listed investments

	The group		The charity	
	2022	2021	2022	2021
	£	£	£	£
Fair value at the start of the year	-	-	-	-
Additions at cost	500,000	-	500,000	-
Disposal proceeds	-	-	-	-
Net gain / (loss) on change in fair value	2,570	-	2,570	-
Fair value at the end of the year	502,570	-	502,570	-

Investments comprise:

	The group		The charity	
	2022	2021	2022	2021
	£	£	£	£
UK Common investment funds	502,570	-	502,570	-
	502,570	-	502,570	-

18a Movements in funds (current year)

	At 1 January 2022 £	Income & gains £	Expenditure & losses £	Transfers £	At 31 December 2022 £
Restricted funds:					
Bill and Melinda Gates Foundation	590,000	2,234,520	(2,410,992)	-	413,527
All-party parliamentary group	68,037	47,500	(38,554)	-	76,983
GlaxoSmithKline plc	70,000	70,000	(140,000)	-	-
Rentokil Initial plc	44,000	4,276	(48,276)	-	-
Medicines for Malaria Venture	30,000	76,063	(106,063)	-	-
RBM Partnership to End Malaria	78,993	57,373	(136,366)	-	-
NVF	-	202,879	(202,879)	-	-
RES Africa	-	380,618	(87,532)	-	293,087
RES Summit	-	177,623	(100,435)	-	77,188
Total restricted funds	881,030	3,250,851	(3,271,096)	-	860,785
Unrestricted funds:					
Resilience reserve	1,474,668	629,427	(1,157,991)	-	946,104
Designated reserve	-	200,000	-	-	200,000
Total unrestricted funds	1,474,668	829,427	(1,157,991)	-	1,146,104
Total funds	2,355,698	4,080,278	(4,429,087)	-	2,006,889

The narrative explaining the purpose of each fund is given at the foot of the note below.

For the year ended 31 December 2022**18b Movements in funds (prior year)**

	At 1 January 2021 £	Income & gains £	Expenditure & losses £	Transfers £	At 31 December 2021 £
Restricted funds:					
Bill and Melinda Gates Foundation	592,524	2,194,099	(2,196,623)	-	590,000
All-party parliamentary group	60,198	34,500	(26,661)	-	68,037
GlaxoSmithKline plc	70,000	70,000	(70,000)	-	70,000
Rentokil Initial plc	-	105,000	(61,000)	-	44,000
Medicines for Malaria Venture	30,000	170,000	(170,000)	-	30,000
RBM Partnership to End Malaria	(33,333)	140,561	(28,235)	-	78,993
Total restricted funds	719,389	2,714,160	(2,552,519)	-	881,030
Unrestricted funds:					
General funds	1,152,979	1,019,980	(698,291)	-	1,474,668
Total funds	1,872,368	3,734,140	(3,250,810)	-	2,355,698

Purposes of restricted funds**Bill and Melinda Gates Foundation**

MNM UK received funding from the Bill and Melinda Gates Foundation. This funding covers a wide range of organisational activities including supporting the charity's campaigns and advocacy work in the UK and beyond.

All-party parliamentary group

MNM UK hosts the All-party parliamentary group on Malaria and NTDs and receives funding from The Leprosy Mission, on behalf of the UK Coalition Against NTDs, Medicines for Malaria Venture, Path MVI, Sightsavers - Uniting to Combat NTDs, and Drugs for Neglected Diseases initiative (DNDi). This funding supports the charity's advocacy work in the UK and beyond.

GlaxoSmithKline plc

GlaxoSmithKline plc (GSK) funded MNMUK's activities in the UK including supporting the charity's campaigns and advocacy work.

Rentokil Initial plc

Funds donated by Rentokil in 2021 were continually deployed in 2022 to support MNMUK's work in Africa.

Medicines for Malaria Venture

Medicines for Malaria Venture (MMV) donated funds to support MNMUK's UK and global advocacy and communications work.

RBM Partnership to End Malaria, NVF, RES Summit

MNMUK received funding from RBM Partnership to End Malaria, NVF, and several sector partners to support the delivery of the Kigali Malaria and NTD Summit and associated communications work.

RES Africa

MNMUK received funding from Motsepe Foundation and long-term supporters Fever-Tree to support the organisation's continued delivery of Africa focused advocacy and communications work.

19 Operating lease commitments payable as a lessee

The charity moved its head office in February 2023 and this has been leased until 31 January 2025. The cost of this is

	2022 £	2021 £
Less than one year	126,654	31,101
Between two and five years	149,682	-
	276,336	31,101

For the year ended 31 December 2022

18b Movements in funds (prior year)

	At 1 January 2021 £	Income & gains £	Expenditure & losses £	Transfers £	At 31 December 2021 £
Restricted funds:					
Bill and Melinda Gates Foundation	592,524	2,194,099	(2,196,623)	-	590,000
All-party parliamentary group	60,198	34,500	(26,661)	-	68,037
GlaxoSmithKline plc	70,000	70,000	(70,000)	-	70,000
Rentokil Initial plc	-	105,000	(61,000)	-	44,000
Medicines for Malaria Venture	30,000	170,000	(170,000)	-	30,000
RBM Partnership to End Malaria	(33,333)	140,561	(28,235)	-	78,993
Total restricted funds	719,389	2,714,160	(2,552,519)	-	881,030
Unrestricted funds:					
General funds	1,152,979	1,019,980	(698,291)	-	1,474,668
Total funds	1,872,368	3,734,140	(3,250,810)	-	2,355,698

Purposes of restricted funds

Bill and Melinda Gates Foundation

MNM UK received funding from the Bill and Melinda Gates Foundation. This funding covers a wide range of organisational activities including supporting the charity's campaigns and advocacy work in the UK and beyond.

All-party parliamentary group

MNM UK hosts the All-party parliamentary group on Malaria and NTDs and receives funding from The Leprosy Mission, on behalf of the UK Coalition Against NTDs, Medicines for Malaria Venture, Path MVI, Sightsavers - Uniting to Combat NTDs, and Drugs for Neglected Diseases initiative (DNDi). This funding supports the charity's advocacy work in the UK and beyond.

GlaxoSmithKline plc

GlaxoSmithKline plc (GSK) funded MNMUK's activities in the UK including supporting the charity's campaigns and advocacy work.

Rentokil Initial plc

Funds donated by Rentokil in 2021 were continually deployed in 2022 to support MNMUK's work in Africa.

Medicines for Malaria Venture

Medicines for Malaria Venture (MMV) donated funds to support MNMUK's UK and global advocacy and communications work.

RBM Partnership to End Malaria, NVF, RES Summit

MNMUK received funding from RBM Partnership to End Malaria, NVF, and several sector partners to support the delivery of the Kigali Malaria and NTD Summit and associated communications work.

RES Africa

MNMUK received funding from Motsepe Foundation and long-term supporters Fever-Tree to support the organisation's continued delivery of Africa focused advocacy and communications work.

19 Operating lease commitments payable as a lessee

The charity moved its head office in February 2023 and this has been leased until 31 January 2025. The cost of this is

	2022 £	2021 £
Less than one year	126,654	31,101
Between two and five years	149,682	-
	276,336	31,101

Emma Orefuwa
Co-founder of the Pan-African Mosquito
Control Association (PAMCA)

“We know how to end malaria. We have the tools and knowledge, especially in Africa. To achieve this we just need to ensure the resources are there to support it.”

malaria
NO MORE
united kingdom

